Simplex Trading, LLC Enlivex Therapeutics Ltd. Transaction History

Simplex Trading, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$2.54 - $4.3 $46,382 - $78,522	18,261 New	18,261 $69,000
Q2 2023 Aug 04, 2023	SELL	$2.51 - $3.71 $95 - $140	-38 Reduced 0.3%	12,675 $33,000
Q1 2023 Apr 27, 2023	BUY	$3.41 - $4.55 $15,549 - $20,748	4,560 Added 55.93%	12,713 $46,000
Q4 2022 Feb 02, 2023	BUY	$3.74 - $4.81 $11,320 - $14,559	3,027 Added 59.05%	8,153 $32,000
Q3 2022 Nov 04, 2022	BUY	$4.11 - $5.87 $3,374 - $4,819	821 Added 19.07%	5,126 $21,000
Q2 2022 Aug 03, 2022	BUY	$3.81 - $8.64 $16,402 - $37,195	4,305 New	4,305 $19,000
Q1 2022 May 02, 2022	SELL	$4.92 - $6.66 $50,006 - $67,692	-10,164 Closed	0 $0
Q4 2021 Feb 23, 2022	BUY	$5.81 - $9.73 $59,052 - $98,895	10,164 New	10,164 $63,000
Q2 2021 Aug 12, 2021	SELL	$8.61 - $12.1 $71,333 - $100,248	-8,285 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$9.26 - $24.0 $63,866 - $165,528	6,897 Added 496.9%	8,285 $91,000
Q4 2020 Feb 02, 2021	BUY	$8.16 - $14.5 $11,326 - $20,126	1,388 New	1,388 $11,000

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $28.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.